Many investors hope to win big on biotech stocks as shares can sky rocket when there is good news. Maxim analyst Gabrielle Zhou explain why there are plenty of promising developments in store for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE).
The analyst recently had an investor meeting with management, where they discussed updates on Zynerba’s three Phase II trials in adult epilepsy, osteoarthritis (OA), and Fragile X syndrome (FXS). Overall, the analyst left the meeting excited as he sees “a best in class, de-risked p2 asset”.
Zhou noted, “We see Zynerba as an excellent value play versus GW Pharma, with a differentiated mode of delivery (transdermal vs. oral) and same active ingredient – CBD (cannabidiol). ZYN002 has a better safety and bioavailability profile, and is a synthetic (vs. plant based), which translates into higher margin and better quality control. Zynerba is also targeting a much larger indication in epilepsy vs. orphan drug indications for GW Pharma.”
Furthermore, “We view Zynerba’s product candidates as de-risked therapeutic alternatives to GW Pharma, based on the validation of CBD in epilepsy (both safety, efficacy and regulatory pathway), as demonstrated by GW Pharma’s Epidiolex in Dravet syndrome (DS) and Lennox-Gastaut sydrome (LGS) in three phase III trials.”
As such, Zhou reiterates a Buy rating on Zynerba Pharmaceuticals shares, with a price target of $32, which implies an upside of 93% from current levels.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Gabrielle Zhou has a yearly average return of -13.3% and a 34.5% success rate. Zhou has a -1.9% average return when recommending ZYNE, and is ranked #4393 out of 4570 analysts.
All the 8 analysts polled by TipRanks (in the past 12 months) rate Zynerba stock a Buy. With a return potential of 94%, the stock’s consensus target price stands at $32.25.